Found 6 articles for: "Tranexamic Acid"
Efficacy and Tolerability of a Topical Pigment-Correcting Serum in Melasma and Postinflammatory Hyperpigmentation
July 2026 | Volume 25 | Issue 7 | Original Article | 596 | Copyright © July 2026
Background: Melasma and postinflammatory hyperpigmentation (PIH) are common disorders of hyperpigmentation of key aesthetic concern. This study assessed the efficacy and tolerabi...
Read MoreEfficacy, Safety, Satisfaction, Adherence to Treatment With Nano-Formulated Cysteamine Tranexamic Acid Cream to Treat Melasma
July 2024 | Volume 23 | Issue 7 | Original Article | 529 | Copyright © July 2024
Background: Melasma is a chronic pigmentary disorder. In this study, an innovative cream combining cysteamine and tranexamic acid (TXA) was assessed.Objectiv...
Read MoreOptimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus
April 2023 | Volume 22 | Issue 4 | Original Article | 386 | Copyright © April 2023
Because of its complex pathogenesis, chronicity, and high rates of recurrence, melasma is regarded as a challenging skin disorder. Topical treatments are often offered as first-line therapy. Howe...
Read MoreOral Tranexamic Acid for the Treatment of Melasma: A Case Series and Novel Dosing Regimen
April 2022 | Volume 21 | Issue 4 | Original Article | 393 | Copyright © April 2022
Melasma is a common disorder affecting millions of people around the world.1 It is a condition that can disrupt one’s self-esteem and overall quality of life.2 Melasma is c...
Read MoreA Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma
March 2022 | Volume 21 | Issue 3 | Editorials | 321 | Copyright © March 2022
Oral tranexamic acid (TXA) is a relatively new treatment option for melasma. It is thought to reduce hyperpigmentation through inhibition of the plasminogen/plasmin pathway with resulting decreases in...
Read MoreThe Use of Tranexamic Acid to Prevent and Treat Post-Inflammatory Hyperpigmentation
March 2021 | Volume 20 | Issue 3 | Editorials | 344 | Copyright © March 2021
The risk of post-inflammatory hyperpigmentation (PIH) in patients undergoing dermatologic procedures is well known. It is especially common after laser procedures and chemical peels but can be seen wi...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.